Melanoma: all 3,073 studies

Page 9 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV MelanomaCompletedNCT02306850Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedNCT02302339Phase 2Results posted
• Phase IIB TL + YCWP + DC in MelanomaCompletedNCT02301611Phase 2Results posted
• Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 MutationsCompletedNCT02296112Phase 2Results posted
• PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous MelanomaTerminatedNCT02288897Phase 3Results posted
• Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected MelanomaTerminatedNCT02263508Phase 3Results posted
• RTA 408 Capsules in Patients With Melanoma - REVEALCompletedNCT02259231Phase 1/2Results posted
• FDG-PET in Advanced MelanomaTerminatedNCT02236546Not applicableResults posted
• Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesTerminatedNCT02230306Phase 2Results posted
• Intratumoral Injections of LL37 for MelanomaCompletedNCT02225366Phase 1/2Results posted
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results posted
• Crizotinib in High-Risk Uveal Melanoma Following Definitive TherapyCompletedNCT02223819Phase 2Results posted
• Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for MelanomaCompletedNCT02211131Phase 2Results posted
• High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryTerminatedNCT02203604Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)CompletedNCT02180061Phase 1Results posted
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
• Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT02158520Phase 2Results posted
• A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)CompletedNCT02156804Phase 2Results posted
• A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)CompletedNCT02155322Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveTerminatedNCT02153905Phase 1/2Results posted
• A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)CompletedNCT02130466Phase 1/2Results posted
• A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedNCT02129075Phase 2Results posted
• Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR AgonistsCompletedNCT02126579Phase 1/2Results posted
• GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain MetastasesCompletedNCT02115139Phase 2Results posted
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaTerminatedNCT02111863Phase 2Results posted
• Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT02107755Phase 2Results posted
• Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line TherapyCompletedNCT02101008Phase 2Results posted
• Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic RadiosurgeryTerminatedNCT02097732Phase 2Results posted
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
• Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticCompletedNCT02094872Phase 2Results posted
• Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)CompletedNCT02089685Phase 1/2Results posted
• MK-3475 in Melanoma and NSCLC Patients With Brain MetastasesCompletedNCT02085070Phase 2Results posted
• Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaCompletedNCT02083354Phase 2Results posted
• Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaCompletedNCT02073123Phase 1/2Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing MelanomaTerminatedNCT02062359Phase 2Results posted
• Infrared Lymphangiography as a Method of Sentinel Node IdentificationCompletedNCT02057393Not applicableResults posted
• Immunotherapy Study for Patients With Stage IV MelanomaTerminatedNCT02054520Phase 2Results posted
• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced MelanomaTerminatedNCT02050321Phase 2Results posted
• Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainCompletedNCT02039947Phase 2Results posted
• Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaCompletedNCT02032810Phase 1Results posted
• CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT02027935Phase 2Results posted
• Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene LaherparepvecCompletedNCT02014441Phase 2Results posted
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
• A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma PatientsCompletedNCT02009397Phase 1/2Results posted
• Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin DiftitoxTerminatedNCT02009384Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaCompletedNCT01993719Phase 2Results posted
• Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsCompletedNCT01990859Phase 2Results posted
• Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989572Phase 3Results posted
• A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected MelanomaCompletedNCT01986712Results posted
• Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and MetabolitesTerminatedNCT01978236Phase 2Results posted
• Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)CompletedNCT01974752Phase 3Results posted
• MSB0010445 and Stereotactic Body Radiation Therapy in Advanced MelanomaTerminatedNCT01973608Phase 2Results posted
• Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV MelanomaTerminatedNCT01970527Phase 2Results posted
• A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaCompletedNCT01970358Phase 1Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerCompletedNCT01967823Phase 2Results posted
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsCompletedNCT01962103Phase 1/2Results posted
• Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV MelanomaCompletedNCT01961115Phase 2Results posted
• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01950390Phase 2Results posted
• The Effects of Treatment With Vemurafenib on the Immune System in Advanced MelanomaTerminatedNCT01942993Phase 2Results posted
• Trametinib With GSK2141795 in BRAF Wild-type MelanomaCompletedNCT01941927Phase 2Results posted
• Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)CompletedNCT01928940Phase 2Results posted
• Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01927419Phase 2Results posted
• A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic MelanomaCompletedNCT01910181Phase 1Results posted
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaCompletedNCT01909453Phase 3Results posted
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedNCT01902173Phase 1/2Results posted
• Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant MelanomaCompletedNCT01898403Not applicableResults posted
• BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 MutationCompletedNCT01894672Phase 2Results posted
• Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by SurgeryCompletedNCT01886235Not applicableResults posted
• Dendritic Cell Vaccines + Dasatinib for Metastatic MelanomaCompletedNCT01876212Phase 2Results posted
• Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell CarcinomaTerminatedNCT01874119Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)CompletedNCT01866319Phase 3Results posted
• A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced MelanomaTerminatedNCT01864538Phase 2Results posted
• HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4Results posted
• Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedNCT01844505Phase 3Results posted
• Utility of Novel BRAF Test for MelanomaCompletedNCT01840527Results posted
• Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic MelanomaTerminatedNCT01838200Phase 1Results posted
• Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by SurgeryCompletedNCT01835145Phase 2Results posted
• Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaCompletedNCT01827111Phase 2Results posted
• A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF MelanomaTerminatedNCT01826448Phase 1Results posted
• LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaTerminatedNCT01820364Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular MelanomaTerminatedNCT01814046Phase 2Results posted
• The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With MelanomaTerminatedNCT01813214Phase 2Results posted
• NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic MelanomaTerminatedNCT01810016Phase 1Results posted
• Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic MelanomaCompletedNCT01807182Phase 2Results posted
• A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaTerminatedNCT01801358Phase 1/2Results posted
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 4Results posted
• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)CompletedNCT01783938Phase 2Results posted
• A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant MelanomaCompletedNCT01781572Phase 1/2Results posted
• Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain MetastasesCompletedNCT01781026Phase 2Results posted
• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.TerminatedNCT01777776Phase 1/2Results posted
• Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
• A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic MelanomaCompletedNCT01765569Phase 1Results posted
• A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)CompletedNCT01765543Phase 1Results posted
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaCompletedNCT01763164Phase 3Results posted
• Combined BRAF-Targeted Therapy & Immunotherapy for MelanomaTerminatedNCT01754376Phase 2Results posted
• Vitamin D Supplementation in Cutaneous Malignant Melanoma OutcomeCompletedNCT01748448Phase 3Results posted
• Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor SamplesCompletedNCT01744860Results posted
• Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic MelanomaCompletedNCT01740557Phase 1/2Results posted
• CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant MelanomaTerminatedNCT01740401Phase 2Results posted

← Melanoma overview